Iniparib from MedChemExpress | Biocompare.com

Be the first to write a review!

Citations:

Supplier Page from
MedChemExpress for
Iniparib

Description

Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer

Product Specs
ItemIniparib
CompanyMedChemExpress
Price $101.00Supplier Page View Company Product Page
Catalog NumberHY-12015
Quantity10 mM * 1 mL
ApplicationsBioactivity, Structure and function analysis, ELISA, SDS-PAGE, Western blotting
Purity99.74%
TypeChemical
Molecular Weight292.03
FormulaC₇H₅IN₂O₃
Research AreaCancer

Add to Compare List

MedChemExpress

MedChemExpress

1 Deer Park Drive, Suite F

MONMOUTH JUNCTION, NJ 08852

United States

Phone: US Tel: 609-228-6898
US Fax: 609-228-5909
EU Tel: +4686500910

Email: sales@medchemexpress.com
eu.sales@MedChemExpress.com

Company Profile

Website: medchemexpress.com

(1) Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cellsPloS oneJanuary 1, 2017Yin S, Cheryan VT, Xu L, Rishi AK, Reddy KB.

(2) Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virusProceedings of the National Academy of Sciences of the United States of AmericaApril 24, 2012Ma W, Halweg CJ, Menendez D, Resnick MA.

(3) Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitorClinical cancer research : an official journal of the American Association for Cancer ResearchJanuary 15, 2012Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Ready DB, Soni NB, Ladror US, et al.

(4) A combined liquid Hib (PRP-OMP), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: uncontrolled preliminary clinical trial of immunogenicity and reactogenicityVaccineDecember 1, 1998Nolan T, Hogg G, Darcy MA, Skeljo M, Carlin J.

Be the First to Write a Review!